Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2015

View Archived Issues

ChemoCentryx, a company focusing on chemoattractant receptors, reviews company outlook

Novel synthetic medium-size compounds mimic functions of antibodies

New evidence provided on SEMA4D as a promising target for MS

3SBio acquires contract manufacturer Sirton Pharmaceuticals

PXT-864 pleodrug improves biological AD-related features

RestorGenex compound granted FDA orphan status for glioblastoma multiforme

Aclaris Therapeutics reports data from phase IIb trial of A-101

Actavis to acquire Auden Mckenzie

Hybrigenics extends partnership with Servier for ubiquitin-specific protease inhibitors

Pfizer aims to improve access to Prevenar 13 in poorest countries

Redx Pharma patents Hedgehog signaling pathway inhibitors

Takeda reports development of RORgamma-t antagonists

Anti-IL-32 MAbs described in ImmunoQure patent

Academic researchers prepare and test ALK inhibitors

Abide Therapeutics divulges MGL inhibitors

National University of Singapore presents peptide inhibitors of FXI

NRX-1074 improves depression scores in phase I study

CF-602 shows promise for sexual dysfunction in preclinical studies

Cutanea Life Sciences initiates phase II trial of CLS-003 for cutaneous warts

PlantForm initiates financing round to fund development of biosimilars

Boehringer Ingelheim studies effect of tiotropium and olodaterol Respimat on COPD exacerbations

Forest initiates pediatric phase I/II trial of ceftaroline fosamil

Radius Health initiates phase I trial of RAD-1901 in breast cancer

Amgen and Onyx file applications to expand approval of carfilzomib in the E.U. and U.S.

Janssen closes collaboration and license agreement with MacroGenics for MGD-011

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...